Dimethylfumarate is approved for the treatment of multiple sclerosis and psoriasis and is also a strong activator of the nuclear factor erythroid 2-related factor 2 (Nrf2), a well-known antioxidant transcription factor that restores cellular redox homeostasis [110]. Here, NFE2L2 is linked to psoriasis.